Across TCGA pan-cancer cohorts, D2HGDH Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated D2HGDH data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher D2HGDH Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated D2HGDH expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, LUAD, and DLBC are the cancer types where D2HGDH Mutation most reproducibly stratifies survival.